Nothing Special   »   [go: up one dir, main page]

Staniek et al., 2019 - Google Patents

TRAIL-R1 and TRAIL-R2 mediate TRAIL-dependent apoptosis in activated primary human B lymphocytes

Staniek et al., 2019

View HTML
Document ID
17979423396405557446
Author
Staniek J
Lorenzetti R
Heller B
Janowska I
Schneider P
Unger S
Warnatz K
Seidl M
Venhoff N
Thiel J
Smulski C
Rizzi M
Publication year
Publication venue
Frontiers in immunology

External Links

Snippet

The maintenance of B cell homeostasis requires a tight control of B cell generation, survival, activation, and maturation. In lymphocytes upon activation, increased sensitivity to apoptotic signals helps controlling differentiation and proliferation. The death receptor Fas is important …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumor necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Similar Documents

Publication Publication Date Title
Staniek et al. TRAIL-R1 and TRAIL-R2 mediate TRAIL-dependent apoptosis in activated primary human B lymphocytes
Barrow et al. The natural cytotoxicity receptors in health and disease
JP7254870B2 (en) Construction of chimeric antibody receptors (CARs) and methods of their use
Tian et al. The role of GITR/GITRL interaction in autoimmune diseases
Degli-Esposti To die or not to die—the quest of the TRAIL receptors
Yang et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells
Grell et al. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF‐R1 activation by endogenous membrane‐anchored TNF
Thompson et al. BAFF binds to the tumor necrosis factor receptor–like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population
Van Kooten et al. CD40-CD40 ligand: a multifunctional receptor-ligand pair
JP2021129588A (en) Composition and methods for regulating inhibitory interactions in genetically engineered cells
CN110662834B (en) Method for culturing natural killer cells using transformed T cells
JP7250519B2 (en) Fusion protein of PD-1 and 4-1BB
EP3720950A1 (en) Reducing fratricide of immune cells expressing nkg2d-based receptors
Betzler et al. The transcriptional program during germinal center reaction-a close view at GC B cells, Tfh cells and Tfr cells
KR20190110531A (en) Improved NK Cell Based Therapies
TW202039538A (en) Suicide gene
Danish et al. TRAIL-R3/R4 and Inhibition of TRAIL Signalling in Cancer
Goodwin et al. The TRAIL of death
Lee et al. Molecular and temporal control of restimulation-induced cell death (RICD) in T lymphocytes
US20220143089A1 (en) Modified immune effector cells with increased resistance to cell death
Abdool Tumor recognition by CTL and NK cells: Importance of activating (LFA-1, NKG2D) receptors, ligands (ICAM-1) and cytokines (IL-18, IL-2) on tumor destruction
EP3712257A1 (en) Modified natural killer cells with increased resistance to cell death
Danish et al. Signalling in Cancer
Lee Characterization of a novel receptor CS1 in human lymphocytes; studies in natural killer cells and B-lymphocytes
Wei et al. Cancer gene therapy via NKG2D and FAS pathways